Mannitol

證據等級: L5

預測適應症: 10 個

Mannitol: From an Unrecorded Original Indication to Nephrogenic Syndrome of Inappropriate Antidiuresis

One-Sentence Summary

Mannitol’s original approved indication is not recorded in this evidence pack (no Danish marketing authorisations and no listed original indications were found for DrugBank ID DB00742). The TxGNN model predicts potential activity in Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), a rare V2-receptor gain-of-function disorder, but this is currently supported by 0 clinical trials and only 1 tangentially related publication, making the evidence purely theoretical at this stage.

Quick Overview

Item	Content
Original Indication	Not documented in available data (no licenses or original indications on file)
Predicted New Indication	Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD)
TxGNN Prediction Score	99.97%
Evidence Level	L5
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for Mannitol is not available in this evidence pack (flagged as a High-severity data gap, DG002). What can be drawn from the evidence pack itself is that Mannitol is functionally an osmotic diuretic — a class known to increase free-water excretion by raising tubular fluid osmolarity.

NSIAD is a rare condition in which the vasopressin V2 receptor is constitutively active independent of ADH, producing an antidiuretic (water-retaining, hyponatremic) state. Standard management relies on fluid restriction, urea, or vaptan-class V2-receptor antagonists. The theoretical rationale for Mannitol is that, as an osmotic diuretic, it could promote free-water excretion and help correct the hyponatremia seen in NSIAD.

However, this link is mechanistic reasoning only. The single supporting publication is a general review on pitfalls in evaluating hyponatremia and does not evaluate Mannitol as a treatment for NSIAD specifically. No clinical trials, case reports, or preclinical studies directly testing Mannitol in NSIAD were identified.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26706473	2016	Review	European Journal of Internal Medicine	General review of common diagnostic pitfalls in evaluating hyponatremia; does not evaluate Mannitol as a treatment for NSIAD

Denmark Market Information

Mannitol currently has no registered marketing authorisations in Denmark under this dataset (market status: not marketed; total authorisations: 0).

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. (No key warnings, contraindications, or drug-interaction data were found in this evidence pack — a Blocking-severity gap, DG001, that prevents a formal safety pre-screen.)

Conclusion and Next Steps

Decision: Hold

Rationale: The NSIAD prediction rests on a plausible but unverified mechanistic hypothesis (osmotic diuresis promoting free-water clearance), with no clinical trials and only one indirectly relevant review article. Evidence Level L5 (model prediction only) does not support advancing beyond preliminary research review.

To proceed, the following is needed:

TFDA/SmPC label data (warnings, contraindications) — currently a blocking gap for any safety pre-screen (DG001)
Detailed mechanism of action documentation for Mannitol (DG002)
Confirmation of Mannitol’s original approved indication(s), which are currently unrecorded
Preclinical or case-level evidence directly testing Mannitol’s effect on serum sodium/free-water clearance in NSIAD or similar SIAD-spectrum conditions
Denmark market/registration status confirmation, since the drug is currently listed as not marketed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.